The potential for clinically significant drug-drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetine/paroxetine or sertraline.

被引：0
|
作者：
Preskorn, SH
Shah, R
Silkey, B
Neff, M
Golbeck, A
Choi, J
机构：
[1] Vet Affairs Med Ctr, Wichita, KS USA
[2] Inst Psychiat Res, Wichita, KS USA
[3] Vet Integrated Serv Network, Bay Pines, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2003.11.266
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P71 / P71
页数：1
相关论文
共 50 条
  • [41] USE OF PBPK MODELING FOR DRUG-DRUG INTERACTIONS PREDICTION OF RIFAPENTINE ON OTHER DRUGS BY INDUCTION OF CYP3A4/5 AND CYP2B6
    Nicolas, Olivier
    Vermet, Helene
    Demers, Brigitte
    Boulenc, Xavier
    Sultan, Eric
    Donat, Francois
    Farenc, Christine
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S49 - S49
  • [42] An Assessment of Drug-Drug Interactions: The Effect of Desvenlafaxine and Duloxetine on the Pharmacokinetics of the CYP2D6 Probe Desipramine in Healthy Subjects
    Patroneva, Albena
    Connolly, Sandra M.
    Fatato, Penny
    Pedersen, Ron
    Jiang, Qin
    Paul, Jeffrey
    Guico-Pabia, Christine
    Isler, Jennifer A.
    Burczynski, Michael E.
    Nichols, Alice I.
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (12) : 2484 - 2491
  • [43] Physiologically Based Pharmacokinetic Model Verification and Improvement for CYP2D6-mediated Drug-drug Interaction Prediction
    Ning, Miaoran
    Posada, Maria M.
    Hall, Stephen D.
    Dickinson, Gemma L.
    FASEB JOURNAL, 2017, 31
  • [44] EVALUATION OF A PXR-CAR-CYP3A4/3A7-CYP2D6-CYP2C9 MULTIPLE HUMANIZED MOUSE MODEL TO PREDICT DRUG-DRUG INTERACTIONS IN MAN
    Scheer, Nico
    Kapelyukh, Yury
    McLaughlin, Lesley A.
    McMahon, Mike
    Rode, Anja
    Henderson, Colin J.
    Wolf, C. Roland
    DRUG METABOLISM REVIEWS, 2015, 47 : 81 - 82
  • [45] Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm
    Ito, K
    Hallifax, D
    Obach, RS
    Houston, JB
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (06) : 837 - 844
  • [46] DEVELOPMENT OF A PBPK MODEL OF CYP3A AND CYP2C19 DOWNREGULATION BY INTERLEUKIN-6 AND ESOMEPRAZOLE: PREDICTION OF DISEASE-DRUG AND DRUG-DRUG INTERACTIONS
    Lenoir, Camille
    Niederer, Amine
    Rollason, Victoria
    Desmeules, Jules Alexandre
    Daali, Youssef
    Samer, Caroline Flora
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (SUPPL 1) : 2 - 2
  • [47] Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient
    Lorenzini, Kuntheavy I.
    Calmy, Alexandra
    Ambrosioni, Juan
    Assouline, Benjamin
    Daali, Youssef
    Fathi, Marc
    Rebsamen, Michela
    Desmeules, Jules
    Samer, Caroline F.
    AIDS, 2012, 26 (18) : 2417 - 2418
  • [48] The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2D6 Substrates
    Rougee, Luc R. A.
    Mohutsky, Michael A.
    Bedwell, David W.
    Ruterbories, Kenneth J.
    Hall, Stephen D.
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (11) : 1819 - 1827
  • [49] Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes
    Xu, Miao
    Zheng, Liang
    Zeng, Jin
    Xu, Wenwen
    Jiang, Xuehua
    Wang, Ling
    PHARMACOTHERAPY, 2021, 41 (03): : 277 - 290
  • [50] A software tool to adjust codeine dose based on CYP2D6 gene-pair polymorphisms and drug-drug interactions
    Saab, Yolande
    Nakad, Zahi
    PHARMACOGENOMICS JOURNAL, 2023, 23 (6): : 217 - 224
12345